Asian Pacific Journal of Cancer Prevention

  • 제13권9호
  • /
  • Pages.4531-4536
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Intervention Effects of Nedaplatin and Cisplatin on Proliferation and Apoptosis of Human Tumour Cells in Vitro

  • Su, Xiang-Yu (Department of Oncology, Zhong-Da Hospital, Southeast University Clinical Medical School) ;
  • Yin, Hai-Tao (Department of Oncology, Zhong-Da Hospital, Southeast University Clinical Medical School) ;
  • Li, Su-Yi (Department of Oncology, Zhong-Da Hospital, Southeast University Clinical Medical School) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiang Su Cancer Hospital and Research Institute) ;
  • Tan, Hua-Yang (Department of Chemotherapy, Yixing People's Hospital) ;
  • Dai, Hong-Yu (Department of Respiratory Medicine, Nanjing Chest Hospital) ;
  • Shi, Fang-Fang (Department of Oncology, Zhong-Da Hospital, Southeast University Clinical Medical School)
  • 발행 : 2012.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To study synergistic effects of nedaplatin and cisplatin on three human carcinoma cell lines (esophageal carcinoma cell line Eca-109, ovarian carcinoma Skov-3 and cervical carcinoma Hela). Methods: Inhibition effects were evaluated by MTT assay and cell apoptosis was detected by flow cytometry. In addition, changes of Ki-67, Bax and Bcl-2 at mRNA and protein levels were quantified by RT-PCR and Western blotting. Results: Growth inhibition in each cell lines was dose-dependent after exposure to nedaplatin or cisplatin alone. The interaction of the two drugs was synergistic at higher concentrations according to the median-effect principle. The inhibition rates with nedaplatin, cisplatin and combined treatment were $41.9{\pm}4.1%$, $47.4{\pm}2.9%$, $52.5{\pm}0.9%$(Eca-109), $39.0{\pm}1.26%$, $45.0{\pm}1.45%$, $56.2{\pm}1.44%$ (Skov-3) and $44.8{\pm}2.11%$, $46.9{\pm}0.99%$, $56.6{\pm}1.83%$ (Hela) respectively, with increase in apoptosis. Compared with the nedaplatin or cisplatin alone treatment group, the combinative treatment group's Ki-67 and bcl-2 mRNA (protein) expression was decreased while that of Bax mRNA (protein) was increased. Conclusion: Compared to the effects of nedaplatin or cisplatin alone at high concentrations, combination of nedaplatin and cisplatin at low concentrations proved to be much more effective for inhibition of proliferation and the induction of apoptosis in the Eca-109, Skov-3 and Hela cell lines.

키워드

참고문헌

  1. Adachi S, Ogasawara T, Wakimoto E et al (2001). Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. Cancer, 91, 74-9. https://doi.org/10.1002/1097-0142(20010101)91:1<74::AID-CNCR10>3.0.CO;2-6
  2. Brabec V, Kasparkova J (2002). Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Update, 5, 147-61. https://doi.org/10.1016/S1368-7646(02)00047-X
  3. Chou TC (2007). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 59, 621-81.
  4. Kim R, Minami K, Nishimoto N, et al (2001). Enhancement of antitumor effect by ntratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol, 18, 363-7.
  5. Koshiyama M, Kinezaki M, Uchida T, Sumitomo M (2005). Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res, 25, 4499-502.
  6. Kunihiko K, Shoji K, Toshihiko T, et al(1995). In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. J Cancer Res Clin Oncol, 121, 715-20. https://doi.org/10.1007/BF01213317
  7. Li S, Wang L, Lin Y, et al (2008). Reduction Nedaplatin combined with cisplatin as first-line therapy treat advanced esophageal carcinoma. Tumour, 28, 446-9.
  8. Liu W, Li S, Huang X, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  9. Nial JW, Shonagh W, Gemma E, et al (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 39, 8113-27. https://doi.org/10.1039/c0dt00292e
  10. Nishida M, Satoh Y, Nishide K, et al (1999). Phase I study of a combination chemotherapy of nedaplatin and cisplatin. Gan To Kagaku Ryoho, 26, 2209-15.
  11. Pasetto LM, D'Andrea MR, Brandes AA, et al (2006). The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol, 60, 59-75. https://doi.org/10.1016/j.critrevonc.2006.02.003
  12. Risa T, Yasushi T, Yoshihiro S, et al (2005). In vitro sequencedependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol, 56, 279-85. https://doi.org/10.1007/s00280-004-0991-y
  13. Taguchi T, Wakui A, Nabeya K, et al (1992). A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother, 19, 483-8.
  14. Takeuchi H, Ozawa S, Ando N, et al (2003). Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol, 10, 792-800. https://doi.org/10.1245/ASO.2003.10.014
  15. Takeki U, Jyoji Y, Mikinori T, et al (2011). Comparative nephrotoxicity of cisplatin and nedaplatin:mechanisms and histopathological characteristics. Toxicol Pathol, 24, 87-94. https://doi.org/10.1293/tox.24.87
  16. Tanaka R, Takii Y, Shibata Y, et al (2005). In vitro sequencedependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol, 56, 279-85. https://doi.org/10.1007/s00280-004-0991-y
  17. Uehara T, Watanabe, Itoh F, et al (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol, 79, 451-60. https://doi.org/10.1007/s00204-005-0648-6
  18. Yao X, Panichpisal K, Kurtzman N, et al (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334, 115-24. https://doi.org/10.1097/MAJ.0b013e31812dfe1e

피인용 문헌

  1. Expression of bcl-2 and p53 in Induction of Esophageal Cancer Cell Apoptosis by ECRG2 in Combination with Cisplatin vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1397
  2. 顺铂联合热处理对术中回收血红细胞及其中混杂的肝肿瘤细胞株 (HepG2) 的影响 vol.16, pp.5, 2015, https://doi.org/10.1631/jzus.B1400224
  3. A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors vol.6, pp.1, 2016, https://doi.org/10.1038/srep36670
  4. MicroRNA and target mRNA selection through invasion and cytotoxicity cell modeling and bioinformatics approaches in esophageal squamous cell carcinoma vol.38, pp.2, 2017, https://doi.org/10.3892/or.2017.5776
  5. Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells vol.70, pp.3, 2018, https://doi.org/10.1007/s10616-018-0197-5
  6. Chemoresistance to Cancer Treatment: Benzo-α-Pyrene as Friend or Foe? vol.23, pp.4, 2018, https://doi.org/10.3390/molecules23040930